top of page

Patient experience

OMIDRIA provides an improved patient experience

OMIDRIA significantly improved postoperative day11 visual acuity across a wide age range4

Of the 641 eyes of 389 patients who underwent cataract surgery, 260 eyes were administered phenylephrine 1.0%/ketorolac 0.3% and 381 eyes received epinephrine in the irrigation solution intraoperatively.4

Immediate improvement in postoperative visual acuity may be attributed to the anti-inflammatory properties of OMIDRIA.4

Reduced complications

Welcome to a cascade of positive outcomes

OMIDRIA blocks the inflammatory cascade and reduces complications4*

Fewer intraoperative and postoperative complications with OMIDRIA, including capsular tears, lens decentration, retained lens fragments, macular puckering, and retinal detachment.1*

*Single-center, retrospective case review.4

†Retrospective, 2-cohort study.13

About OMIDRIA

Clinical Data

Insights from OMIDRIA real-world evidence and and clinical data

Close up of a surgeon during surgery

Pupil stability and fewer PEDs

OMIDRIA effectively maintains pupil dilation

Percentage of patients with pupil diameter <6 mm at the start of lens implantation

  • 96% of OMIDRIA-treated patients had pupil diameter ≥6 mm at the start of lens implantation1-3

  • Real-world evidence shows that OMIDRIA can benefit ALL patient types, not just high-risk patients4-6

OMIDRIA is the 1st and only FDA-approved non-opioid, NSAID-containing treatment for maintaining pupil size and reducing postoperative pain by preventing intraoperative miosis.1

Patient consulting with healthcare professional

Learn more about Dedicated Access and Support for your patients

Close up of patient preparing for surgery

Miosis can occur at any time during cataract surgery

References:

  1. Omidria [prescribing information]. Bellevue, WA: Rayner Surgical Inc. April 2023.

  2. Rayner. Data on file.

  3. Lindstrom RL, Loden JC, Walters TR, et al. Intracameral phenylephrine and ketorolac injection (OMS302) for maintenance of intraoperative pupil diameter and reduction of postoperative pain in intraocular lens replacement with phacoemulsification. Clin Ophthalmol. 2014;8:1735-1744.

  4. Rosenberg ED, Nattis AS, Alevi D, et al. Visual outcomes, efficacy, and surgical complications associated with intracameral phenylephrine 1.0%/ketorolac 0.3% administered during cataract surgery. Clin Ophthalmol. 2018;12:21-28.

  5. Bucci FA Jr, Michalek B, Fluet AT. Comparison of the frequency of use of a pupil expansion device with and without an intracameral phenylephrine and ketorolac injection 1%/0.3% at the time of routine cataract surgery. Clin Ophthalmol. 2017;11:1039-1043.

  6. Visco D. Effect of phenylephrine/ketorolac on iris fixation ring use and surgical times in patients at risk of intraoperative miosis. Clin Ophthalmol. 2018;12:301-305.

  7. Donnenfeld ED, Whitaker JS, Jackson MA, Wittpenn J. Intracameral ketorolac and phenylephrine effect on intraoperative pupil diameter and postoperative pain in cataract surgery. J Cataract Refract Surg. 2017;43(5):597-605.

  8. Matossian C. Clinical and economic outcomes in cataract surgery using phenylephrine 1.0%-ketorolac 0.3% in a real-world setting. Presented at: ASCRS ASOA Annual Meeting 2018; April 13-17, 2018; Washington, DC.

  9. Walter K, Delwadia N, Coben J. Continuous intracameral phenylephrine–ketorolac irrigation for miosis prevention in femtosecond laser–assisted cataract surgery: reduction in surgical time and iris manipulation. J Cataract Refract Surg. 2019;45(4):465-469.

  10. Florio V, Cowan L, Prusakiewicz JJ, Bentley E, Waterbury LD. Ocular tissue distribution of ketorolac after administration of OMS302 to dogs during IOL replacement. E-poster presented at: American Society of Cataract and Refractive Surgery (ASCRS) and American Society of Ophthalmic Administrators (ASOA) Annual Meeting; April 17-21, 2015; San Diego, CA.

  11. Waterbury LD. Alternative drug delivery for patients undergoing cataract surgery as demonstrated in a canine model. J Ocul Pharmacol Ther. 2018;34:154-160.

  12. Wittpenn JR, Silverstein S, Heier J, Kenyon KR, Hunkeler JD, Earl M; the Acular LS for Cystoid Macular Edema (ACME) Study Group. A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs steroid alone in low-risk cataract surgery patients. Am J Ophthalmol. 2008;146(4):554-560.

  13. Visco DM, Bedi R. Effect of intracameral phenylephrine 1.0%–ketorolac 0.3% on postoperative cystoid macular edema, iritis, pain, and photophobia after cataract surgery. J Cataract Refract Surg. 2020;46(6):867-872.

  14. Silverstein SM, Rana VK, Stephens R, et al. Effect of phenylephrine 1.0%–ketorolac 0.3% injection on tamsulosin-associated intraoperative floppy-iris syndrome. J Cataract Refract Surg. 2018;44(9):1103-1108.

Indications and Usage

OMIDRIA® is added to ophthalmic irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.

Important Safety Information

OMIDRIA must be added to irrigating solution prior to intraocular use.
OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients.


Systemic exposure to phenylephrine may cause elevations in blood pressure.


Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory drugs (NSAIDs), or have a past medical history of asthma.


The most commonly reported adverse reactions at ≥ 2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.


Please see the Full Prescribing Information for OMIDRIA.


You are encouraged to report Suspected Adverse Reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Indications and Usage

OMIDRIA® is added to ophthalmic irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.

Important Safety Information

OMIDRIA must be added to irrigating solution prior to intraocular use.
OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients.


Systemic exposure to phenylephrine may cause elevations in blood pressure.


Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory drugs (NSAIDs), or have a past medical history of asthma.


The most commonly reported adverse reactions at ≥ 2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.


Please see the Full Prescribing Information for OMIDRIA.


You are encouraged to report Suspected Adverse Reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

bottom of page